Summary
Gilead Sciences, Inc. (GILD) reported $6.95 billion in total revenues for the second quarter of 2024, a 5% increase compared to the same period last year. This growth was primarily driven by strong performance in HIV, Oncology, and Liver Disease segments. Diluted earnings per share (EPS) for the quarter were $1.29, a significant increase from $0.83 in Q2 2023, reflecting improved revenues and lower operating expenses. Despite a strong Q2 performance, the six-month period ending June 30, 2024, showed a net loss of $2.56 billion. This was largely attributable to a significant acquired in-process R&D charge of $3.9 billion related to the CymaBay acquisition and a $2.4 billion impairment charge on IPR&D assets for Trodelvy's NSCLC indication. The company also reported a decrease in cash and cash equivalents, primarily due to the CymaBay acquisition and dividend payments. Gilead's balance sheet remains robust, but investors should monitor the impact of significant R&D charges and ongoing litigation.
Financial Highlights
55 data points| Revenue | $6.95B |
| Cost of Revenue | $1.54B |
| Gross Profit | $5.41B |
| SG&A Expenses | $1.38B |
| Operating Expenses | $4.31B |
| Operating Income | $2.64B |
| Net Income | $1.61B |
| EPS (Basic) | $1.29 |
| EPS (Diluted) | $1.29 |
| Shares Outstanding (Basic) | 1.25B |
| Shares Outstanding (Diluted) | 1.25B |
Key Highlights
- 1Total revenues increased by 5% year-over-year to $6.95 billion for the second quarter of 2024, driven by growth in HIV, Oncology, and Liver Disease product sales.
- 2Diluted earnings per share (EPS) for the second quarter of 2024 was $1.29, a substantial increase from $0.83 in the prior year's second quarter.
- 3The six-month period ending June 30, 2024, resulted in a net loss of $2.56 billion, primarily due to significant R&D charges and impairments.
- 4A major factor impacting the six-month results was a $3.9 billion acquired in-process R&D expense related to the acquisition of CymaBay Therapeutics.
- 5The company recorded a $2.4 billion impairment charge related to Trodelvy's non-small cell lung cancer (NSCLC) indication following disappointing Phase 3 study results.
- 6Cash and cash equivalents decreased significantly from $6.09 billion at the beginning of the year to $2.77 billion by the end of the second quarter, largely due to acquisitions and dividend payments.
- 7Gilead continues to face significant legal proceedings, including patent litigation with generic manufacturers and antitrust and product liability lawsuits.